{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:36:52Z","timestamp":1792201012899,"version":"4.4.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:p>\n                    This study evaluates the clinical efficacy and biomarker effects of quetiapine combined with magnesium valproate in patients with schizophrenia. A total of 156 patients diagnosed with schizophrenia were randomly assigned to 2 groups: 1 received magnesium valproate monotherapy (n\u2005=\u200578), and the other received combined therapy with quetiapine and magnesium valproate (n\u2005=\u200578). Both groups were treated for 8 weeks. Serum brain-derived neurotrophic factor and GFAP concentrations were measured before and after treatment. Clinical efficacy was assessed using the positive and negative syndrome scale, Montreal Cognitive Assessment, and a schizophrenia-specific quality of life scale. Adverse events were monitored and compared. After 8 weeks of treatment, serum brain-derived neurotrophic factor concentrations increased significantly in the combination group (628.63\u2005\u00b1\u2005154.09 pg\/mL) compared with the monotherapy group (520.78\u2005\u00b1\u2005133.44 pg\/mL,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Meanwhile, GFAP concentrations decreased to 2.16\u2005\u00b1\u20050.23 \u03bcg\/L in the combination group versus 2.36\u2005\u00b1\u20050.30 \u03bcg\/L in the monotherapy group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Positive and negative syndrome scale total scores decreased more substantially in the combination group (101.41\u2005\u00b1\u200511.36 to 74.54\u2005\u00b1\u20058.41) than in the monotherapy group (101.33\u2005\u00b1\u20059.85 to 89.22\u2005\u00b1\u20059.06,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Montreal Cognitive Assessment scores improved to 26.15\u2005\u00b1\u20053.36 in the combination group compared with 22.24\u2005\u00b1\u20053.64 in the monotherapy group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Quality of life scores also improved more in the combination group (total: 73.41\u2005\u00b1\u20055.49) than in the monotherapy group (82.92\u2005\u00b1\u20055.57,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001; lower scores indicate better quality of life). The incidence of adverse reactions was comparable between groups, occurring in 8 of 78 patients (10.26%) in the combination group and 7 of 78 patients (8.97%) in the monotherapy group (\u03c7\u00b2=0.074,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.786). Quetiapine combined with magnesium valproate offers superior clinical benefits over monotherapy in patients with schizophrenia. It significantly improves psychiatric symptoms, cognitive function, and quality of life, likely through modulation of neurotrophic and glial activity, with good tolerability and safety.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045955","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:01:05Z","timestamp":1764169265000},"page":"e45955","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic efficacy of quetiapine combined with magnesium valproate in schizophrenia: Impact on serum BDNF and GFAP levels"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7226-4146","authenticated-orcid":false,"given":"Mingsong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology, The First People\u2019s Hospital of Jiangxia District, Wuhan, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mcna.2022.05.005","article-title":"Schizophrenia: one name, many different manifestations.","volume":"107","author":"Faden","year":"2023","journal-title":"Med Clin North Am"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"MS19053BR3C","DOI":"10.4088\/JCP.MS19053BR3C","article-title":"Current treatment options and emerging agents for schizophrenia.","volume":"81","author":"Correll","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia.","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system.","volume":"29","author":"Shu","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.encep.2021.12.006","article-title":"Quetiapine-associated thrombocytopenic purpura in a young man with a first episode schizophrenia.","volume":"49","author":"Fekih-Romdhane","year":"2023","journal-title":"Encephale"},{"key":"R6-20260514","first-page":"183","article-title":"A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: updating the evidence and gaps.","volume":"30","author":"Jeun","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1111\/bcp.14928","article-title":"Dose-response association of acute-phase quetiapine treatment with risk of new-onset hypothyroidism in schizophrenia patients.","volume":"87","author":"Zhao","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"114838","DOI":"10.1016\/j.bbr.2023.114838","article-title":"Mechanism of cognitive impairment and white matter damage in the MK-801 mice model of schizophrenia treated with quetiapine.","volume":"461","author":"Yu","year":"2024","journal-title":"Behav Brain Res"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/02698811231200020","article-title":"Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: a systematic review and dose-response model-based network meta-analysis.","volume":"37","author":"Terao","year":"2023","journal-title":"J Psychopharmacol"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/01612840.2018.1494987","article-title":"Valproate for schizophrenia.","volume":"39","author":"Scruth","year":"2018","journal-title":"Issues Ment Health Nurs"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2021.07.011","article-title":"Association between valproate treatment for acute phase schizophrenia and risk of new onset hypothyroidism.","volume":"235","author":"Zhao","year":"2021","journal-title":"Schizophr Res"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/metabo13010134","article-title":"Therapeutic and toxic effects of valproic acid metabolites.","volume":"13","author":"Shnayder","year":"2023","journal-title":"Metabolites"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/17460441.2020.1795125","article-title":"Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts?","volume":"15","author":"Jankovi\u0107","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/cancers13143409","article-title":"valproic acid and breast cancer: state of the art in 2021.","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/YPG.0000000000000237","article-title":"Brain-derived neurotrophic factor and schizophrenia.","volume":"29","author":"Di Carlo","year":"2019","journal-title":"Psychiatr Genet"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bj.2020.01.001","article-title":"Brain-derived neurotrophic factor and mental disorders.","volume":"43","author":"Lin","year":"2020","journal-title":"Biomed J"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000514126","article-title":"A meta-analysis of brain-derived neurotrophic factor effects on brain volume in schizophrenia: genotype and serum levels.","volume":"80","author":"Ahmed","year":"2021","journal-title":"Neuropsychobiology"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jpsychires.2022.10.022","article-title":"Effects of brain-derived neurotrophic factor (BDNF) on the Schizophrenia model of animals.","volume":"156","author":"Shi","year":"2022","journal-title":"J Psychiatr Res"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/schbul\/sbac188","article-title":"Brain-derived neurotrophic factor val66met genotype modulates latent inhibition: relevance for schizophrenia.","volume":"49","author":"Buhusi","year":"2023","journal-title":"Schizophr Bull"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/alz.12879","article-title":"Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with A\u03b2-PET, neurodegeneration, and cognition.","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"108624","DOI":"10.1016\/j.intimp.2022.108624","article-title":"Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease - A systematic review.","volume":"107","author":"Heimfarth","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpsychires.2021.09.012","article-title":"Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder.","volume":"144","author":"Steinacker","year":"2021","journal-title":"J Psychiatr Res"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1038\/s41598-020-71060-4","article-title":"Plasma \u03b2-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.","volume":"10","author":"Rodrigues-Amorim","year":"2020","journal-title":"Sci Rep"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1570163815666181008151718","article-title":"Aripiprazole: an FDA approved bioactive compound to treat schizophrenia-a mini review.","volume":"17","author":"Kumar","year":"2020","journal-title":"Curr Drug Discov Technol"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chc.2019.08.017","article-title":"Childhood-onset schizophrenia and early-onset schizophrenia spectrum disorders: an update.","volume":"29","author":"Driver","year":"2020","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"R26-20260514","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/14656566.2022.2145884","article-title":"Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.","volume":"23","author":"de Bartolomeis","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"113464","DOI":"10.1016\/j.psychres.2020.113464","article-title":"The effectiveness of adjunct music therapy for patients with schizophrenia: a meta-analysis.","volume":"293","author":"Jia","year":"2020","journal-title":"Psychiatry Res"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2022.02.010","article-title":"Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia.","volume":"241","author":"Zhao","year":"2022","journal-title":"Schizophr Res"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/bcp.15734","article-title":"A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real-world data.","volume":"89","author":"Hao","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S1092852920001285","article-title":"Valproate for schizophrenia: ambrosia?","volume":"26","author":"Naguy","year":"2021","journal-title":"CNS Spectr"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpsychires.2019.08.011","article-title":"Randomized controlled trial of adjunctive Valproate for cognitive remediation in early course schizophrenia.","volume":"118","author":"Ibrahim","year":"2019","journal-title":"J Psychiatr Res"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1566523218666180302163029","article-title":"Dysfunction in Brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, parkinson\u2019s and alzheimer\u2019s diseases.","volume":"18","author":"Mohammadi","year":"2018","journal-title":"Curr Gene Ther"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1192\/bjp.2024.113","article-title":"Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals.","volume":"225","author":"Kikuchi","year":"2024","journal-title":"Br J Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:05:32Z","timestamp":1778756732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":33,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045955","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}